Sign in
Not yet taking people in NetherlandsPhase 2

Anakinra for children with cancer who have sepsis and strong inflammation in intensive care

Tests anakinra added to usual care in children with cancer and sepsis.

Key facts

Who runs it
Prinses Maxima Centrum voor Kinderoncologie B.V.
Where
Utrecht, NetherlandsSee the 2 sites
Registry title
THRILL: Treat Hyperinflammation in child oncology study
Status
Not yet recruiting
Phase
Phase 2
People taking part
76 people, planned
Started
1 May 2026
Expected to end
1 May 2029
Type of study
Interventional
Record updated
30 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teenagers with cancer (or after a stem-cell transplant) who are in intensive care with a suspected or confirmed infection and signs of strong inflammation.

Age
From eight months to 18 years.
Sex
All sexes can join.
Disease stage
Admitted to intensive care with suspected or confirmed infection, a Phoenix Sepsis score of 2 or more, and serum ferritin of 2000 µg/L or more at admission. An underlying malignancy or a stem-cell transplant is required.
Earlier treatment
Cannot have had targeted anti-inflammatory treatment (biologic or JAK inhibitor) in the week before intensive care, anakinra in the month before, or TNF alfa blocking agents (within 5 times the drug's half-life).
Biomarker or test result
Serum ferritin of 2000 µg/L or more at intensive care admission.

Main reasons for not taking part

  • Younger than eight months or weight under 10 kg (22 lb)
  • Severe liver dysfunction as defined in the record
  • Pregnant or breastfeeding, or not willing to use contraception
  • Treatment limitations in place, such as a do-not-resuscitate order
  • Known allergy to anakinra or to proteins from Escherichia coli

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Children and adolescents with an age between eight months and 18 years admitted to ICU
  • An underlying malignancy (according to ICD-10 code) or post-HCT at time of ICU admission
  • Admitted to ICU with suspected or confirmed infection
  • Phoenix Sepsis score total ≥ 2
  • Serum ferritin level ≥ 2000 µg/L at ICU admission, so called Phenotype 1 patients
  • Written informed consent/assent from patients and/or from parents or legal guardians for minor patients according to local law and regulations

Who cannot take part

  • Pregnant or lactating patients, or sexually active female patients of childbearing potential not willing to use a highly effective method of contraception for the duration of study therapy and pregnancy testing prior to inclusion
  • Sexually active, fertile male patients, not willing to use an effective method of contraception, for the duration of study therapy
  • Patients are excluded if predefined treatment limitations are in place at the time of ICU admission. Treatment limitations are defined as a do-not-resuscitate (DNR) order or any restriction on the use of mechanical ventilation, vasopressor or inotropic support, continuous renal replacement therapy, or extracorporeal membrane oxygenation (ECMO)
  • Any prior underlying severe organ toxicity, for example CF patients with severe pulmonary dysfunction, patients with cardiac failure, patients with chronic renal failure, etc. either due to cancer, cancer treatment or prior causes
  • Treatment with targeted anti-inflammatory therapy for hyperinflammation (biologic or JAK inhibitor) in the week prior to ICU admission
  • Previous treatment with anakinra in the month prior to the ICU admission
  • Previous treatment with TNF alfa blocking agents (within 5x half-life of the drug)
  • Known hypersensitivity to anakinra or to any of the other ingredients, or to proteins produced by Escherichia coli
  • Severe liver dysfunction according to the criteria of the European and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition including biochemical evidence of severe liver injury (no chronic impairment) and coagulopathy not corrected by vitamin K (prothrombin time (PT) ≥15 sec or international normalized ratio (INR) ≥ 1.5 with evidence of hepatic encephalopathy or PT ≥ 20 sec or INR > 2 with or without encephalopathy)
  • Age younger than eight months and/or weight < 10 kg
  • Participation in a clinical trial which prohibits participation in another clinical trial with an IMP
  • Patients for whom informed consent was not obtained

Where in Netherlands

  • Prinses Maxima Centrum voor Kinderoncologie B.V.Utrecht, NetherlandsNot yet recruiting
  • Universitair Medisch Centrum UtrechtUtrecht, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

To assess the efficacy of early administration of the recombinant IL-1R antagonist anakinra as adjunctive treatment to standard of care (SoC) in pediatric cancer patients admitted to ICU with sepsis and signs of hyperinflammation on 28-day all-cause mortality compared to a historical cohort receiving standard of care only.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
THRILL: Treat Hyperinflammation in child oncology study - A single arm, historically controlled, open label phase II study on the efficacy and safety of the recombinant interleukin (IL)-1R antagonist anakinra in pediatric cancer patients admitted to the intensive care with sepsis and signs of hyperinflammation
Plain-language title
Anakinra for children with cancer who have sepsis and strong inflammation in intensive careGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 September 2026